➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
AstraZeneca
Baxter
Mallinckrodt
McKinsey

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RETISERT

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Retisert

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00032396 A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration Unknown status Bausch & Lomb Incorporated Phase 2 2001-11-01 A study evaluating Retisert in patients with age-related macular degeneration
NCT00032396 A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration Unknown status Control Delivery Systems Phase 2 2001-11-01 A study evaluating Retisert in patients with age-related macular degeneration
NCT00502541 Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema Completed Bausch & Lomb Incorporated Phase 2/Phase 3 2001-09-01 This was a multi-center, randomized, masked, parallel-group, controlled study in patients with diabetic macular edema, comparing RetisertTM (0.59 mg) with control therapy (standard of care (SOC) - repeat macular grid laser or observation). The objective was to evaluate the safety and efficacy of the intravitreal fluocinolone acetonide implant in the treatment of patients with diabetic macular edema.
NCT00543296 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed Bausch & Lomb Incorporated Phase 4 2004-03-01 The purpose of this study is to collect data on patients with severe uveitis that have required re-implantation of the sustained-release fluocinolone drug delivery device due to depletion of study drug in their previous implanted device.
NCT00543296 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed Duke University Phase 4 2004-03-01 The purpose of this study is to collect data on patients with severe uveitis that have required re-implantation of the sustained-release fluocinolone drug delivery device due to depletion of study drug in their previous implanted device.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Retisert

Condition Name

Condition Name for Retisert
Intervention Trials
Diabetic Macular Edema 3
Uveitis, Posterior 2
Uveitis Affecting the Posterior Segment. 1
Uveitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Retisert
Intervention Trials
Uveitis 5
Macular Edema 3
Edema 3
Uveitis, Posterior 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Retisert

Trials by Country

Trials by Country for Retisert
Location Trials
United States 5
China 1
Korea, Republic of 1
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Retisert
Location Trials
North Carolina 2
Maryland 1
Texas 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Retisert

Clinical Trial Phase

Clinical Trial Phase for Retisert
Clinical Trial Phase Trials
Phase 4 3
Phase 2/Phase 3 1
Phase 2 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Retisert
Clinical Trial Phase Trials
Completed 4
Unknown status 2
Not yet recruiting 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Retisert

Sponsor Name

Sponsor Name for Retisert
Sponsor Trials
Bausch & Lomb Incorporated 4
Glenn Jaffe 1
Duke University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Retisert
Sponsor Trials
Other 10
Industry 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
McKinsey
Boehringer Ingelheim
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.